Reviews/Dry Eye Disease Treatment/Autologous serum in Sjogren syndrome dry eye
Autologous Serum · DED-AS-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across the trials here, autologous serum eye drops generally moved dry-eye measures in the right direction for people with Sjögren syndrome. In a Sjögren-specific trial [9] serum beat a cyclosporine-plus-artificial-tears combination on symptom scores, and another [7] showed better eye-surface staining and tear stability, though that same trial found no change in symptom scores or one tear-production test. A single-arm Sjögren-and-graft-versus-host study [10] also reported symptom improvement but had no comparison group. Much of the supporting evidence comes from general dry-eye patients not specified as having Sjögren [1][2][8], so some of the benefit is inferred rather than shown directly. The panel landed short of the top tier because the symptom signal is not uniform, the Sjögren trials compared serum against active treatments rather than a dummy drop, and the studies are small.
Two Sjögren-specific randomized trials report benefit: [9] (65 patients) found autologous serum superior on OSDI symptom score (p=0.004) with significant within-group gains in Schirmer, tear break-up time and OSDI, while [7] (38 patients) found significant improvement in corneal and conjunctival staining and tear break-up time (p<0.005) but no significant change in OSDI or Schirmer. Single-arm [10] (24 patients) reported a significant OSDI decrease (p<0.01) in a graft-versus-host or Sjögren cohort. These are reinforced by general severe dry-eye trials in which serum outperformed artificial tears [1] (OSDI decrease 50% vs 22%, p=0.002), [2] (OSDI mean difference -10.3, 95% CI -13.6 to -7.0), and [8] (significant improvement in tear break-up time, staining and symptoms). A crossover trial [6] found the autologous OSDI change non-significant (-4.2, 95% CI -9.5 to 1.2). The contested point: The evidence divides on whether the symptomatic (OSDI) benefit holds specifically in Sjögren: the best-controlled primary-Sjögren trial [7] found OSDI unchanged, while [9] found serum superior on OSDI. The symptomatic case therefore rests mainly on [9] and the uncontrolled [10], with [6] showing a non-significant change.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The two directly-Sjögren RCTs use active comparators (AS vs PRP in [7], AS vs cyclosporine in [9]), not placebo, so neither isolates the AS-versus-vehicle effect specifically in Sjögren; [9]'s from-baseline gains are uncontrolled.
The symptomatic signal is inconsistent on-target: [7], the cleanest primary-Sjögren RCT, reports that 'The Schirmer I values, OSDI scores ... did not significantly change', and [6] reports autologous OSDI change non-significant (-4.2, 95% CI -9.5 to 1.2).
Where it remains uncertain. The cleanest primary-Sjögren trial [7] reports that OSDI and Schirmer did not significantly change, and [6] reports a non-significant autologous OSDI change, so symptomatic benefit in Sjögren is not uniform.
Aleatory
Sjögren-specific samples are small (N=38 [7], 65 [9], 24 [10]), so null objective findings such as the unchanged Schirmer and OSDI in [7] may reflect underpowering rather than absence of effect.
Epistemic
The Sjögren trials compare serum against active treatments (platelet-rich plasma [7], cyclosporine plus artificial tears [9]); the corpus holds no placebo- or vehicle-controlled Sjögren trial, so the serum-versus-dummy effect in Sjögren is unmeasured.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independent RCT: AS beats artificial tears symptomatically (general DES).
“Autologous serum treatment showed a statistically significant (p = 0.002) higher OSDI decrease (50%) versus conventional treatment (22%).”
Panel auditInternal validity: medium · scope of inference: Adult severe dry eye syndrome patients, symptom improvement over 2 weeks; etiology not specified as Sjogren.Key limitations: n=12 · short 2-week treatment · no objective improvement (OXFORD, TBUT) · population not Sjogren-specific
Large multicentre RCT consistency that AS outperforms artificial tears.
“The ASEDs group showed significantly greater improvement in all these measures than the artificial tears group (all P values < 0.05).”
Panel auditInternal validity: high · scope of inference: Moderate-to-severe dry eye syndrome patients in China over 12 weeks; Sjogren status not reported.Key limitations: population not Sjogren-specific · etiology mix unknown
Primary-Sjögren RCT: significant objective ocular-surface improvement with AS.
“Corneal and conjunctival staining scores and TBUT significantly improved at 4 and 12 weeks in both groups (all p < 0.005).”
Panel auditInternal validity: medium · scope of inference: Primary Sjogren syndrome dry eye; before-after change on ocular surface signs over 12 weeks.Key limitations: n=38 · no non-serum control · OSDI and Schirmer did not change · improvement shown within-group only
Autologous serum gave significantly greater OSDI decrease and higher TBUT than artificial tears.
Panel auditInternal validity: medium · scope of inference: Severe dry eye syndrome patients refractory to conventional treatment; symptom and tear-film stability over 1 month.Key limitations: n=20 · no difference in Schirmer/OXFORD · population not Sjogren-specific
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Directionally consistent, independently replicated benefit in Sjögren-inclusive RCTs, held to Likely by mixed symptomatic signal, active comparators, and small, indirect samples.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No placebo-controlled Sjögren trial. The two on-target Sjögren RCTs use active comparators [7][9], so the corpus cannot separate serum's effect from that of any drop or the natural course in Sjögren. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-masked randomized trial in primary Sjögren dry eye comparing autologous serum against a vehicle or preservative-free artificial-tear control, powered on OSDI.
Open question: Does autologous serum improve dry-eye symptoms and signs in Sjögren syndrome relative to a placebo or vehicle drop? Why it is still open: Both Sjögren RCTs in the corpus use active comparators [7][9] and the only placebo-free symptom gain comes from the uncontrolled [10], so no vehicle-controlled Sjögren estimate exists.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19